CLOs on the Move

VytronUS

www.vytronus.com

 
VytronUS, Inc. was formed in 2006 to harness the imaging and therapeutic capabilities of ultrasound energy to treat cardiac arrhythmias, starting with atrial fibrillation. We recognize that today`s marketed technologies have limitations. Only a new energy source, such as collimated ultrasound, can shift the treatment paradigm to more predictable outcomes. We strive to make a complicated procedure simple. Ease of use guides every aspect of our design philosophy. At VytronUS, patient safety is always our first priority and improved efficacy is our mission. We look forward to making our products available to doctors and their patients in the near future.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.vytronus.com
  • 658 North Pastoria Ave
    Sunnyvale, CA USA 94085
  • Phone: 408.730.1333

Executives

Name Title Contact Details

Similar Companies

Diagnostic Hybrids

Diagnostic Hybrids, Inc. is a Athens, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.

Invirion Diagonostics

Invirion Diagonostics is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Total Environmental Service Technologies Inc

Total Environmental Service Technologies Inc is a Peru, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Kiff Analytical

Kiff Analytical is a Davis, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.